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OBJECTIVES The purpose of the study was to investigate if apoptosis occurs in skeletal muscle myocytes
and its relation to exercise intolerance in patients with chronic heart failure (CHF).
BACKGROUND Intrinsic abnormalities of skeletal muscle frequently limit exercise tolerance in CHF patients.
Recently, apoptosis has been detected in cardiac myocytes of patients with CHF, suggesting
that apoptosis may contribute to the reduced contractile force. The presence and regulation
of apoptosis in skeletal myocytes of patients with CHF remains to be defined.
METHODS Skeletal muscle biopsies (m. vastus lateralis) of 34 CHF patients (New York Heart
Association functional class II–III) and eight age-matched healthy control subjects were
analyzed by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick
end-labeling for the presence of apoptosis, and by immunohistochemistry and videodensito-
metrical quantification for inducible nitric oxide synthase (iNOS) and Bcl-2 expression.
Maximal oxygen consumption (VO2max) was determined by ergospirometry.
RESULTS Apoptosis was detected in 16/34 (47%) patients with CHF and in none of the healthy
subjects. Patients with apoptosis-positive skeletal muscle myocytes exhibited a significantly
lower VO2max (12.0 6 3.7 vs. 18.2 6 4.4 ml/kg/min; p 5 0.0005), a higher iNOS expression
(6.8 6 3.6 vs. 3.7 6 2.6% iNOS-positive stained tissue area; p 5 0.015) and a lower Bcl-2
expression (1.0 6 0.3 vs. 1.4 6 0.4% Bcl-2–positive tissue area; p 5 0.03) as compared with
patients with apoptosis-negative biopsies.
CONCLUSIONS These results indicate that apoptosis is frequently found in skeletal muscle obtained from
CHF patients, which is associated with significant impairment of functional work capacity.
In skeletal muscle of these patients, iNOS and Bcl-2 are possibly involved in the regulation
of apoptosis. (J Am Coll Cardiol 1999;33:959–65) © 1999 by the American College of
Cardiology
Chronic heart failure (CHF) is not only associated with an
increased mortality, but also with exercise intolerance and
early fatigue. It has been frequently pointed out, however,
that the level of activity tolerated by individual patients
could not be predicted by classical parameters of left
ventricular performance (1,2). Therefore, considerable at-
tention has been focused on the role of peripheral factors,
such as regional blood flow and skeletal muscle, as deter-
minants of work capacity. Intrinsic abnormalities of skeletal
muscle including atrophy (3), impaired function (4), change
in fiber type composition (5–7) and altered metabolism
(8–10) have been implicated. These intrinsic muscle alter-
ations are thought to be partially responsible for the exercise
intolerance associated with CHF, although the pathophys-
iologic link to compromised left ventricular performance has
escaped definition so far.
Recently apoptotic cells were detected in myocardial
biopsies obtained from patients with arrhythmogenic right
ventricular dysplasia (11) or end-stage heart failure (12,13).
The authors concluded that the loss of myocytes due to
apoptosis results in a loss of contractile function and
therefore may contribute to the progressive myocardial
dysfunction in these patients. Dysregulation of the apopto-
tic process can lead to a spectrum of defects ranging from
embryonic lethality to disintegration of tissues by loss of
cells (14). Therefore, tight regulation of this process is
essential, and several genes have been identified to play a
crucial role in its regulation. In particular, dominant onco-
genes such as c-myc, Bcl-2 and tumor suppressor genes such
as p-53 have been shown to be potent regulators of
apoptosis (15,16). Beside these oncogenes, nitric oxide
(NO) has been reported to function as a pro- and anti-
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apoptotic factor (reviewed in [17]). The contradicting ef-
fects of NO in apoptosis regulation can be rationalized by a
dose-dependent phenomenon, with low concentrations act-
ing antiapoptotic, and high concentrations being proapop-
totic (17). Particularly, conditions associated with high
levels of NO elaborated by inducible NO synthase (iNOS)
seem to favor apoptosis (18,19).
On the basis of these observations and the knowledge
that the expression of iNOS is significantly increased in
skeletal myocytes of patients with CHF (20), we hypothe-
sized that apoptosis may not only be involved in myocardial
but also in skeletal muscle dysfunction in patients with
CHF.
METHODS
Patients. Thirty-four male patients #70 years old with
CHF (New York Heart Association functional class II to
III) as a result of dilated cardiomyopathy or ischemic heart
disease and eight sedentary normal individuals were studied.
Healthy subjects had a normal physical examination, elec-
trocardiogram, chest-X-ray, M-mode and two-dimensional
echocardiographic evaluation. All patients had clinical, ra-
diologic and echocardiographic signs of CHF and a reduced
left ventricular ejection fraction (#40%), as assessed by
angiography. Exclusion criteria were diabetes mellitus,
chronic alcohol abuse, immunosuppressive therapy, renal
failure, chronic lung disease, primary valvular disease, he-
reditary or acquired neuromuscular disorders or recent
myocardial infarction (less than three months). To deter-
mine the onset of disease, patients were asked to identify the
time point of their first clinical symptoms.
The protocol of this study was approved by the Ethics
Committee of the University of Leipzig, and written in-
formed consent was obtained from all subjects before the
beginning of the study.
Exercise testing and respiratory gas exchange measure-
ments. All individuals underwent a baseline exercise test to
exclude myocardial ischemia and significant ventricular
tachyarrhythmias and to familiarize the subjects with er-
gospirometry. Exercise testing was performed on a cali-
brated, electronically braked bicycle in an upright position.
Work load was increased progressively every 3 min in steps
of 25 W beginning at 25 W. Exercise was terminated when
patients were physically exhausted or developed severe
dyspnea or dizziness. Respiratory gas exchange data were
determined continuously throughout the exercise test as
recently described (21,22).
Skeletal muscle biopsy. Percutaneous needle biopsies were
obtained from the middle part of the m. vastus lateralis
under local anesthesia as described in detail by Bergstro¨m
(23). The biopsies were fixed with 4% buffered formalde-
hyde and subsequently paraffin embedded.
In situ detection of apoptotic cells. For the in situ
detection of apoptotic cells, the method of terminal deoxy-
nucleotidyl transferase (TdT)-mediated deoxyuridine
triphosphate nick end-labeling (TUNEL) with several
modifications was applied. Paraffin sections (3 mm) of the
tissue material were dewaxed with xylene (2 3 5 min at
room temperature [RT]) and rehydrated with graded dilu-
tions of ethanol in water (100%; 75%; 50%, water). After
rehydration, the tissue was treated with proteinase K
(40 mg/ml; 5 min at RT) followed by several washing steps
(3 3 5 min water at RT). To block the internal peroxidase
activity the slides were incubated for 20 min with 0.6%
hydrogen peroxide in 100% methanol. Before the addition
of the TdT labeling mixture (25 U TdT [Promega, Madi-
son, Wisconsin], 1 nmol digoxigenin-11-deoxyuridine-
triphosphate [Boehringer Mannheim, Mannheim, Ger-
many] in 400 ml of equilibration buffer [200 mmol/L
cacodylat, 25 mmol/L Tris-HCl pH 6.6, 250 mg/ml bovine
serum albumin and 2.5 mmol/L cobalt chloride]) the
sections were incubated for 15 min at RT in equilibration
buffer. After 1 h incubation at 37°C with the TdT labeling
mixture the sections were rinsed (3 3 5 min at RT) in
Tris–buffer (50 mmol/L Tris pH 7.6, 150 mmol/L NaCl)
to remove the unincorporated digoxigenin label. To detect
the digoxigenin-labeled DNA the following steps were
performed: blocking of unspecific binding sides with 2%
fetal calf serum in Tris–buffer (15 min at RT), 30-min
incubation with an antidigoxigenin antibody at dilution
1:1,000 (Boehringer Mannheim, Mannheim, Germany),
extensive rinsing (3 3 5 min at RT) with Tris–buffer to
remove the free antibody and incubation of the slides for
30 min at RT with a rabbit antisheep peroxidase–
conjugated antibody at dilution 1:500 in Tris–buffer with
2% fat free milk powder (Dianova GmbH, Hamburg,
Germany). After a final washing step (3 3 5 min with
Tris–buffer) the sections were developed using 3-amino-9-
ethylcarbazole as substrate for peroxidase and counter-
stained with hemotoxylin. As negative control reaction an in
situ detection was performed as described above but without
TdT in the labeling mixture. Positive control samples were
prepared by incubating sections with 10 U/ml deoxyribo-
nuclease I for 20 min at 37°C before treatment with TdT
(24). Four sections of each biopsy were screened for apo-
ptotic nuclei. A sample with at least two positive nuclei per
section was classified as positive. To estimate the apoptotic
index the percentage of positive stained nuclei was calcu-
Abbreviations and Acronyms
CHF 5 chronic heart failure
iNOS 5 inducible nitric oxide synthase
NO 5 nitric oxide
RT 5 room temperature
TdT 5 terminal deoxynucleotidyl transferase
TUNEL 5 terminal deoxynucleotidyl transferase-
mediated deoxyuridine triphosphate nick
end-labeling
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lated in relation to unstained apoptosis-negative nuclei in a
subset of apoptosis-positive skeletal muscle biopsies. The
types of cells staining positive for DNA fragmentation were
further characterized with a monoclonal antiactin antibody
(HFF 35, Dako GmbH, Hamburg, Germany) as described
elsewhere (12).
Detection of iNOS and Bcl-2 by immunohistochemistry.
The expression of iNOS was visualized and quantitated
using an iNOS-specific polyclonal antibody (Transduction
Laboratories, Lexington, Kentucky) and biotinylated tyra-
mid as recently described in detail (20). The specificity of
the antibody is described elsewhere (25,26).
To detect Bcl-2 on paraffin sections from skeletal muscle
biopsies, a specific monoclonal antibody (antihuman Bcl-2,
clone 124; Dako GmbH, Hamburg, Germany) was used.
The immunohistochemical detection was performed as
follows: after deparaffination and rehydration the tissue
sections (4 mm thick) were boiled for 10 min in 10 mmol/L
citrate buffer, pH 6.0 (27). To prevent unspecific binding of
the primary antibody the sections were blocked for 20 min
with blocking solution (1.5% normal horse serum in 4%
nonfat dry milk solubilized in phosphate-buffered saline).
After this blocking step the primary anti-Bcl-2 antibody
was applied (1:40 dilution in blocking solution) onto the
sections, and the reaction was carried out at 37°C for 2 h in
a humified chamber. After rinsing in phosphate-buffered
saline (3 3 5 min at RT) the bound primary antibody was
visualized using the alkaline phosphatase–antialkaline phos-
phatase method (Dako Diagnostika GmbH, Hamburg,
Germany) as described by the company. As negative control
the primary antibody was omitted and replaced by blocking
solution.
Statistical analysis. Values are given as mean 6 SD for all
variables. Single comparisons were performed by nonpara-
metric tests (Mann–Whitney U test or Wilcoxon test), and
a p value of less than 0.05 was considered statistically
significant.
RESULTS
Study group. In 24 patients, dilated cardiomyopathy was
diagnosed based on cardiac catheterization with global
hypokinesis and normal coronary arteries (Table 1). Coro-
nary artery disease was the underlying cause in 10 patients.
All patients received angiotensin-converting enzyme inhib-
itors, and 26 patients (76.4%) were on digitalis. Thirty-one
(91.1%) were treated with diuretics and eight patients
(23.5%) with amiodarone. Twenty-one patients (61.7%)
had a history of at least one episode of left heart decom-
pensation.
Left ventricular ejection fraction (19.6 6 8.0 vs. 70.8 6
5.2%; p , 0.001) and maximal oxygen uptake (15.1 6 5.1
vs. 26.0 6 2.2 ml/kg/min; p 5 0.0001) were significantly
impaired, and a lower body weight (79.7 6 13.7 vs. 92.0 6
13.6 kg; p 5 0.04) was detected as compared with the
healthy control subjects.
Apoptosis in skeletal myocytes and its correlation to
exercise intolerance. Apoptosis could be detected in 16 out
of 34 patients with CHF (47%) by TUNEL staining (Fig.
1A), whereas no apoptose labeling could be observed in
negative controls (omission of terminal transferase in label-
ing mixture). Furthermore, in biopsies of healthy control
patients no staining for apoptosis was observed (Fig. 1B).
Positive apoptotic staining could be observed in all nuclei by
TUNEL after the pretreatment of the sections with de-
oxyribonuclease I (Fig. 1C), whereas no staining after
deoxyribonuclease digestion was detected when TdT was
omitted in the TUNEL reaction (Fig. 1D). Staining of
TUNEL-treated sections with a monoclonal antiactin an-
tibody showed that the TUNEL-positive nuclei are myocyte
nuclei (Fig. 1E and F). Evaluation of the apoptosis-positive
specimens revealed that less than 0.7 6 0.4% of skeletal
myocytes were apoptosis positive. Peak oxygen consumption
was significantly reduced in patients with apoptosis as
compared with patients without apoptosis in skeletal myo-
cytes (12.0 6 3.7 vs. 18.2 6 4.4 ml/kg/min; p 5 0.0005)
(Table 2). Furthermore, patients with apoptosis-positive
skeletal muscle biopsies had a significantly longer history of
the illness (64.3 6 60.2 vs. 25.8 6 42.7 months; p 5 0.02).
No significant relation between the incidence of apoptosis
and other clinical parameters like age, body weight, left
ventricular ejection fraction and cardiac decompensation
events could be detected (Table 2).
Detection of iNOS and Bcl-2 expression and its relation
to apoptosis. Inducible NO synthase protein expression
was detected in all skeletal muscle biopsies of patients with
CHF, whereas in the healthy control subjects no staining








Age (yr) 57.9 6 8.7 55.1 6 8.4
Weight (kg) 79.7 6 13.7 92.0 6 13.6
Ejection fraction (%) 19.6 6 8.0 70.8 6 5.2
VO2max (ml/kg/min) 15.1 6 5.1 26.0 6 2.2









Data presented are mean value 6 SD or percent of patients.
ACE 5 angiotensin-converting enzyme; CHF 5 chronic heart failure; DCM 5
dilated cardiomyopathy; ICM 5 ischemic cardiomyopathy; VO2max 5 maximal
oxygen consumption.
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could be observed (Fig. 2, A and B, Table 2). Quantitative
analysis revealed a significantly higher expression in com-
parison with normal healthy individuals (5.1 6 3.4 vs. 0.8 6
0.7% positive tissue area; p 5 0.0001). Dividing the CHF
patients into an apoptosis-positive and an apoptosis-negative
group, the patients exhibiting apoptosis-positive skeletal mus-
cle myocytes showed a significantly higher iNOS expression
compared with apoptosis-negative patients (6.8 6 3.6 vs.
3.7 6 2.6% positive tissue area; p 5 0.015) (Table 2).
The antiapoptotic factor Bcl-2 could be detected in the
cytosol of skeletal myocytes (Fig. 2C) and showed a 50%
higher expression level in the healthy control group when
compared with CHF patients (1.8 6 0.6 vs. 1.2 6 0.4%
positive tissue area; p 5 0.017). In the negative control
reaction no staining could be observed (Fig. 2D). A sub-
group analysis of CHF patients revealed that apoptosis-
positive patients had a 40% lower level of Bcl-2 expression
than patients with apoptotic-negative skeletal myocytes
(1.0 6 0.3 vs. 1.4 6 0.4% positive stained tissue area; p 5
0.03) (Table 2).
Figure 1. Representative images (3200) of terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end-labeling
reactions or antiactin staining of skeletal muscle biopsies. Nuclei with fragmented deoxyribonucleic acid stained red (arrows) (A) whereas
cells with normal nuclei stained blue (immunoperoxidase staining with hematoxylin counterstaining). Terminal deoxynucleotidyl
transferase-mediated deoxyuridine triphosphate nick end-labeling staining of a skeletal muscle biopsy from a (A) chronic heart failure
(CHF) patient; (B) normal control subject; (C) CHF patient after deoxyribonuclease I pretreatment; (D) CHF patient after
deoxyribonuclease I pretreatment but with the omission of deoxynucleotidyl transferase in the labeling reaction; (E) CHF patient, and (F)
the same as in (E) but counterstained with antiactin is shown. The identical nuclei in E and F are marked with asterisks.
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DISCUSSION
Three important findings emerge from this study: 1) apo-
ptosis occurs not only in the myocardium but also in skeletal
muscle of patients with chronic heart failure, 2) apoptosis in
skeletal myocytes is associated with a lower exercise capac-
ity, and 3) iNOS expression is increased and the expression
of Bcl-2 is reduced in patients with apoptosis-positive
myocytes. These results suggest that iNOS and Bcl-2 may
be involved in the regulatory mechanisms of apoptosis.
Particularly in patients with a long history of CHF, apo-
ptosis may represent another factor contributing to impaired
exercise tolerance.
Apoptosis in skeletal myocytes of patients with CHF.
The concept that accumulation or loss of cells is due to
uncontrolled cell proliferation or abnormal cell death rates
has been amended. The realization that cell death is a
normal process in development and cellular homeostasis has
opened a new avenue for exploration of the causes and
treatment of various diseases (14). In addition to the
beneficial effects of apoptosis, the inappropriate activation of












Age (yr) 60.1 6 7.1 55.9 6 9.5 0.20
Weight (kg) 76.4 6 14.1 82.6 6 12.7 0.21
LVEF (%) 19.6 6 7.9 19.6 6 8.1 0.90
VO2max (ml/kg/min) 12.0 6 3.7 18.2 6 4.4 0.0005*
Duration (months) 64.3 6 60.2 25.8 6 42.7 0.02*
Decompensations
(events/patient)
1.1 6 1.4 0.8 6 1.0 0.60
Medication
ACE inhibitors (%) 100 100
Diuretics (%) 100 83.3
Digitalis (%) 81.2 72.2
Amiodarone (%) 6.2 38.8
*Statistically significant. Data presented are mean value 6 SD or percent of patients.
Apo. 5 apoptosis; LVEF 5 left ventricular ejection fraction; neg. 5 negative;
pos. 5 positive. Other abbreviations as in Table 1.
Figure 2. Representative images of the immunohistochemical detection of inducible nitric oxide synthase (A, B) or Bcl-2 (C, D) of a
skeletal muscle biopsy from a chronic heart failure patient (A, C) and a normal control subject (C, D) (3200).
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programmed cell death may cause or contribute to a variety
of diseases including neurodegenerative disorders and isch-
emic stroke (28,29), acquired immunodeficiency syndrome
(30,31) and ischemic injury (24). Apoptosis is highly regu-
lated, controlled by many different distinct signaling path-
ways, which ultimately converge to activate a common
apoptotic program (14,32).
Terminally differentiated cells, such as myocardial/
skeletal muscle or neuronal cells, are not likely to undergo
apoptosis under natural conditions. Recently, however,
three studies demonstrated histochemical evidence for an
increase of apoptosis in myocardial myocytes of patients
with heart failure (12,13) and reperfusion injury (33). These
authors speculated that apoptosis may lead to a progressive
deterioration in myocardial function, culminating in chronic
cardiomyopathy and end-stage heart failure. One might
hypothesize that apoptosis may contribute to the reduced
aerobic capacity of skeletal muscle in patients with CHF.
This assumption is supported by our finding that pro-
grammed cell death is found in 47% of our CHF patients,
and that its presence is associated with a reduced exercise
capacity. The majority of the apoptotic nuclei are, based on
antiactin staining, skeletal muscle myocytes and not endo-
thelial or satellite cells. This finding further strengthens the
idea that an apoptotic loss of myocytes in patients with
CHF may lead to a reduced contractile force, and therefore
to a reduced functional work capacity. Furthermore, the
finding that patients with apoptosis-positive skeletal myo-
cytes exhibited a longer duration of the disease goes along
with the clinical observation that exercise capacity decreases
with progression of CHF.
At first glance, the observation that only a very small
fraction (0.7 6 0.4%) of cells are apoptotic in skeletal
muscle biopsies of CHF patients seems to be too insignif-
icant to impair functioning of the skeletal muscle. It is
unlikely that we underestimated the number of apoptotic-
positive nuclei in skeletal muscle biopsies of CHF patients,
because 100% of the nuclei stained TUNEL-positive after
deoxyribonuclease I pretreatment. However, as pointed out
by Colucci (34,35), apoptosis is a transient event, lasting
perhaps only a few hours, and the death of even such a small
fraction of nuclei per day could, over a period of months, or
years, lead to a significant loss of functioning myocytes.
Regulatory mechanisms for the induction of apoptosis.
In the current literature a variety of agents are reported to
act either pro- or antiapoptotically (reviewed in [14]). The
Bcl-2 protein, originally discovered by virtue of its involve-
ment in the t(14;18) chromosomal translocation, acts as an
antiapoptotic factor, by preventing the collapse of the
mitochondrial membrane potential or by complexing the
proaptoptotic factor Bax (reviewed in [16]). Nitric oxide
represents another factor that, when produced in high
amounts by iNOS, is capable of inducing the apoptotic
process (reviewed in [17]). Analyzing the skeletal muscle
biopsies of patients with chronic heart failure and dividing
the samples into two groups—apoptosis positive or apopto-
sis negative—a higher iNOS expression and a reduced
expression of Bcl-2 were detected in apoptosis-positive
specimens. On the basis of these results, one might specu-
late that the increased expression of iNOS and the reduction
of the antiapoptotic factor Bcl-2 are involved in the regu-
lation of the apoptotic process in skeletal muscle of patients
with CHF.
Analyzing the iNOS immunohistochemical staining pat-
tern, a diffuse positive staining of the biopsy was observed.
Proceeding from this diffuse staining pattern and the small
tissue area analyzed, one may hypothesize that an ischemic
insult or a cytokine-mediated process is the pathophysio-
logic mechanism for the increased expression of iNOS.
That ischemia and certain cytokines are capable of inducing
iNOS is well described in the literature (36,37). To fully
understand the pathophysiologic mechanism leading to the
induction of iNOS and the apoptotic process in the skeletal
muscle of patients with CHF, further experimental investi-
gations are necessary.
In conclusion, this study demonstrates that apoptosis is
present in about 50% of skeletal muscle biopsies obtained
from patients with CHF. The increased expression of
iNOS, as well as the reduced expression of Bcl-2, are
possible factors for the induction of the apoptotic process in
skeletal muscle myocytes. Most important, the occurrence
of apoptosis is associated with a diminished exercise capacity
of these patients.
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